Arthur He's Stock Ratings

HC Wainwright & Co. Analyst

Arthur He is an analyst at HC Wainwright & Co.. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/28/2024

Overall Average Return

2.68%

Smart Score

51.3%

Overall Average Return Percentile

44th

Number of Ratings

44
Buy NowGet Alert
06/28/2024ADAGBuy Now
Adagene
$2.6687.97%ReiteratesBuy → BuyGet Alert
06/28/2024LVTXBuy Now
LAVA Therapeutics
$1.81231.49%$6 → $6ReiteratesBuy → BuyGet Alert
06/05/2024HOOKBuy Now
HOOKIPA Pharma
$0.61877.2%$5 → $6MaintainsBuyGet Alert
05/28/2024CALTBuy Now
Calliditas Therapeutics
$38.740.67% → $39DowngradeBuy → NeutralGet Alert
05/24/2024CALTBuy Now
Calliditas Therapeutics
$38.7416.16%$50 → $45MaintainsBuyGet Alert
05/22/2024PSTXBuy Now
Poseida Therapeutics
$2.86599.3% → $20ReiteratesBuy → BuyGet Alert
05/20/2024SLDBBuy Now
Solid Biosciences
$5.75178.26% → $16ReiteratesBuy → BuyGet Alert
05/20/2024PRMEBuy Now
Prime Medicine
$5.1793.42% → $10Initiates → BuyGet Alert
05/15/2024BCABBuy Now
BioAtla
$1.37410.95% → $7ReiteratesBuy → BuyGet Alert
05/02/2024PSTXBuy Now
Poseida Therapeutics
$2.86599.3% → $20ReiteratesBuy → BuyGet Alert
04/26/2024HOOKBuy Now
HOOKIPA Pharma
$0.61714.33%$6.5 → $5MaintainsBuyGet Alert
04/22/2024PSTXBuy Now
Poseida Therapeutics
$2.86599.3% → $20ReiteratesBuy → BuyGet Alert
04/15/2024MSCLBuy Now
Satellos Bioscience
→ $1.2Initiates → BuyGet Alert
03/27/2024BCABBuy Now
BioAtla
$1.37410.95%$10 → $7MaintainsBuyGet Alert
03/25/2024HOOKBuy Now
HOOKIPA Pharma
$0.61958.63% → $6.5ReiteratesBuy → BuyGet Alert
03/21/2024LVTXBuy Now
LAVA Therapeutics
$1.81231.49% → $6ReiteratesBuy → BuyGet Alert
03/14/2024SLDBBuy Now
Solid Biosciences
$5.75178.26% → $16ReiteratesBuy → BuyGet Alert
03/11/2024SLDBBuy Now
Solid Biosciences
$5.75178.26%$9 → $16MaintainsBuyGet Alert
03/08/2024PSTXBuy Now
Poseida Therapeutics
$2.86599.3% → $20ReiteratesBuy → BuyGet Alert
02/22/2024CALTBuy Now
Calliditas Therapeutics
$38.7429.07% → $50ReiteratesBuy → BuyGet Alert
12/11/2023PSTXBuy Now
Poseida Therapeutics
$2.86599.3%$15 → $20MaintainsBuyGet Alert
11/27/2023CALTBuy Now
Calliditas Therapeutics
$38.7429.07% → $50ReiteratesBuy → BuyGet Alert
11/17/2023LVTXBuy Now
LAVA Therapeutics
$1.81231.49% → $6ReiteratesBuy → BuyGet Alert
11/08/2023BCABBuy Now
BioAtla
$1.37629.93%$17 → $10MaintainsBuyGet Alert
10/04/2023ADAGBuy Now
Adagene
$2.6687.97% → $5ReiteratesBuy → BuyGet Alert
09/01/2023ADAGBuy Now
Adagene
$2.6687.97% → $5ReiteratesBuy → BuyGet Alert
08/23/2023LVTXBuy Now
LAVA Therapeutics
$1.81231.49%$9 → $6MaintainsBuyGet Alert
08/11/2023HOOKBuy Now
HOOKIPA Pharma
$0.61958.63%$8 → $6.5MaintainsBuyGet Alert
08/08/2023PSTXBuy Now
Poseida Therapeutics
$2.86424.48% → $15ReiteratesBuy → BuyGet Alert
08/02/2023BCABBuy Now
BioAtla
$1.371140.88% → $17ReiteratesBuy → BuyGet Alert
06/12/2023LVTXBuy Now
LAVA Therapeutics
$1.81397.24% → $9ReiteratesBuy → BuyGet Alert
05/23/2023PSTXBuy Now
Poseida Therapeutics
$2.86424.48% → $15ReiteratesBuy → BuyGet Alert
05/15/2023BCABBuy Now
BioAtla
$1.371140.88% → $17ReiteratesBuy → BuyGet Alert
05/12/2023HOOKBuy Now
HOOKIPA Pharma
$0.611202.93% → $8ReiteratesBuy → BuyGet Alert
05/10/2023PSTXBuy Now
Poseida Therapeutics
$2.86424.48% → $15Reiterates → BuyGet Alert
04/21/2023ADAGBuy Now
Adagene
$2.6687.97% → $5Reiterates → BuyGet Alert
04/13/2023LVTXBuy Now
LAVA Therapeutics
$1.81397.24% → $9Reiterates → BuyGet Alert
03/29/2023ADAGBuy Now
Adagene
$2.6687.97% → $5Reiterates → BuyGet Alert
03/24/2023BCABBuy Now
BioAtla
$1.371140.88%$20 → $17MaintainsBuyGet Alert
03/21/2023ADAGBuy Now
Adagene
$2.6687.97% → $5Reiterates → BuyGet Alert
03/16/2023HOOKBuy Now
HOOKIPA Pharma
$0.611202.93% → $8Reiterates → BuyGet Alert
03/10/2023PSTXBuy Now
Poseida Therapeutics
$2.86424.48% → $15Reiterates → BuyGet Alert
02/23/2023PSTXBuy Now
Poseida Therapeutics
$2.86424.48% → $15MaintainsBuyGet Alert
10/25/2022LVTXBuy Now
LAVA Therapeutics
$1.81397.24% → $9Initiates → BuyGet Alert

Recent Analyst Stock Rating News

The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free